Literature DB >> 1906711

Structural and functional characterization of Factor VIII-delta II, a new recombinant Factor VIII lacking most of the B-domain.

N Bihoreau1, P Paolantonacci, C Bardelle, M P Fontaine-Aupart, S Krishnan, J Yon, J L Romet-Lemonne.   

Abstract

A recombinant Factor VIII (Factor VIII-delta II) consists of a unique polypeptide chain of 165 kDa deleted from the major part of the B-domain and from the cleavage site at Arg-1648-Glu-1649 found in plasma-derived Factor VIII. It was expressed in mammalian cells in serum-free medium containing von Willebrand factor and purified by a one-step immunopurification. The recombinant Factor VIII was characterized as a single active peak when subjected to f.p.l.c., in contrast with the plasma-derived molecule. Its coagulant activity was decreased in the presence of EDTA, suggesting that a bivalent ion is required, as for plasma-derived Factor VIII. The activation by thrombin and the inactivation by activated protein C were studied and the resulting molecular forms were analysed by f.p.l.c. and SDS/PAGE. The results clearly demonstrate that, despite the structural differences between plasma-derived and recombinant Factor VIII, activation and inactivation of Factor VIII-delta II generate proteolysed complexes similar to that described for plasma-derived Factor VIII. Thus this deleted recombinant Factor VIII, which is processed similarly to plasma-derived Factor VIII, should be normally integrated in the regulation system of Factor X activation in the blood-coagulation cascade.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1906711      PMCID: PMC1151186          DOI: 10.1042/bj2770023

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  32 in total

1.  Silver stain for proteins in polyacrylamide gels: a modified procedure with enhanced uniform sensitivity.

Authors:  J H Morrissey
Journal:  Anal Biochem       Date:  1981-11-01       Impact factor: 3.365

2.  Structure of human factor VIII.

Authors:  G A Vehar; B Keyt; D Eaton; H Rodriguez; D P O'Brien; F Rotblat; H Oppermann; R Keck; W I Wood; R N Harkins; E G Tuddenham; R M Lawn; D J Capon
Journal:  Nature       Date:  1984 Nov 22-28       Impact factor: 49.962

3.  Molecular cloning of a cDNA encoding human antihaemophilic factor.

Authors:  J J Toole; J L Knopf; J M Wozney; L A Sultzman; J L Buecker; D D Pittman; R J Kaufman; E Brown; C Shoemaker; E C Orr
Journal:  Nature       Date:  1984 Nov 22-28       Impact factor: 49.962

4.  Dissociation of factor VIII procoagulant antigen VIII:CAg and factor VIII related antigen VIIIR:Ag by EDTA - influence of divalent cation on the binding of VIII:CAg and VIIIR:Ag.

Authors:  T H Tran; F Duckert
Journal:  Thromb Haemost       Date:  1983-08-30       Impact factor: 5.249

Review 5.  The factor VIII complex: structure and function.

Authors:  L W Hoyer
Journal:  Prog Clin Biol Res       Date:  1981

6.  Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease.

Authors:  H J Weiss; I I Sussman; L W Hoyer
Journal:  J Clin Invest       Date:  1977-08       Impact factor: 14.808

7.  Factor VIII recombination after dissociation by CaCl12.

Authors:  H A Cooper; T R Griggs; R H Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  1973-08       Impact factor: 11.205

8.  Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V.

Authors:  C A Fulcher; J E Gardiner; J H Griffin; T S Zimmerman
Journal:  Blood       Date:  1984-02       Impact factor: 22.113

9.  Monoclonal antibodies to porcine factor VIII coagulant and their use in the isolation of active coagulant protein.

Authors:  D N Fass; G J Knutson; J A Katzmann
Journal:  Blood       Date:  1982-03       Impact factor: 22.113

10.  Thrombin proteolysis of purified factor viii procoagulant protein: correlation of activation with generation of a specific polypeptide.

Authors:  C A Fulcher; J R Roberts; T S Zimmerman
Journal:  Blood       Date:  1983-04       Impact factor: 22.113

View more
  7 in total

1.  Correlation of rFVIII inactivation with aggregation in solution.

Authors:  Wei Wang; Drew N Kelner
Journal:  Pharm Res       Date:  2003-04       Impact factor: 4.200

2.  First determination of the secondary structure of purified factor VIII light chain.

Authors:  N Bihoreau; M P Fontaine-Aupart; A Lehegarat; M Desmadril; J M Yon
Journal:  Biochem J       Date:  1992-11-15       Impact factor: 3.857

3.  Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa.

Authors:  S W Pipe; R J Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

4.  Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A.

Authors:  G N Nguyen; L A George; J I Siner; R J Davidson; C B Zander; X L Zheng; V R Arruda; R M Camire; D E Sabatino
Journal:  J Thromb Haemost       Date:  2016-11-25       Impact factor: 5.824

5.  Removal of Mannose-Ending Glycan at Asn2118 Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells.

Authors:  Sandrine Delignat; Julie Rayes; Suryasarathi Dasgupta; Bagirath Gangadharan; Cécile V Denis; Olivier D Christophe; Jagadeesh Bayry; Srinivas V Kaveri; Sébastien Lacroix-Desmazes
Journal:  Front Immunol       Date:  2020-03-26       Impact factor: 7.561

Review 6.  Immune Responses to Plasma-Derived Versus Recombinant FVIII Products.

Authors:  Flora Peyvandi; Syna Miri; Isabella Garagiola
Journal:  Front Immunol       Date:  2021-01-22       Impact factor: 7.561

7.  Delivery of factor VIII gene into skeletal muscle cells using lentiviral vector.

Authors:  Hyun Jeong Jeon; Tae Keun Oh; Oak Hee Kim; Seung Taik Kim
Journal:  Yonsei Med J       Date:  2009-12-29       Impact factor: 2.759

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.